Status: Recruiting
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Participants needed: 250
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Jul 8, 2025Locations: 6
Eligibility criteria
Males and females aged 18 to 70 years; [+40]
The patient's decision to withdraw from the study (revocation of informed consen... [+15]